Type 2 & other diabetes

Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study

DiabetologiaPublished Retrospective registry cohort study

Authors' conclusion

There is significant heterogeneity in responses to GLP-1 RA therapy among individuals with type 2 diabetes in routine clinical practice. However, in our study a substantial proportion achieved a reduction in either body weight or HbA1c. Future studies should explore why some individuals achieve either weight loss or HbA1c reduction but not both.

Study context

Population
Adults with T2D initiating liraglutide, semaglutide or dulaglutide, DPV registry
Participants
4,467 adults
Outcome
Changes in HbA1c and body weight; response categories: HbA1c reduction only, weight loss only, both or neither
Follow-up
6 months
Methodological detailsreal-world clinical practice, part of the IMI-SOPHIA project
  • Real-world clinical practice
  • Part of the IMI-SOPHIA project

Main finding

As reported in the abstract

Median absolute HbA1c reduction, mmol/mol (IQR)
5.3 (13.9, −1.0)
Median absolute HbA1c reduction, % (IQR)
0.49% [1.27, −0.09]
Median relative body weight reduction (IQR)
1.43% (4.26, 0)
Meaningful reduction in both HbA1c (≥5.5 mmol/mol [0.5%]) and body weight (≥5%)
14%
HbA1c-only response
36%
Weight-only response
7%

Observational data: associations, not effects.

Further findings

Predictors of response

Men and higher baseline HbA1c more likely HbA1c-only response
both p<0.001
Older age and longer DM duration more likely weight-only response
both p<0.001
Higher baseline body weight and lower eGFR correlated with greater weight reduction
both p<0.05
Lower baseline HbA1c and longer DM duration linked to smaller HbA1c reductions
both p<0.001

Original publication

Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study. Diabetologia. Published 22 May 2025. doi:10.1007/s00125-025-06448-w

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.